Portage Common Stock Shares Outstanding vs Non Current Assets Total Analysis
| PRTG Stock | USD 3.81 0.06 1.55% |
Portage Biotech financial indicator trend analysis is much more than just breaking down Portage Biotech prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Portage Biotech is a good investment. Please check the relationship between Portage Biotech Common Stock Shares Outstanding and its Non Current Assets Total accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.
Common Stock Shares Outstanding vs Non Current Assets Total
Common Stock Shares Outstanding vs Non Current Assets Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Portage Biotech Common Stock Shares Outstanding account and Non Current Assets Total. At this time, the significance of the direction appears to have weak relationship.
The correlation between Portage Biotech's Common Stock Shares Outstanding and Non Current Assets Total is 0.31. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of Portage Biotech, assuming nothing else is changed. The correlation between historical values of Portage Biotech's Common Stock Shares Outstanding and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Portage Biotech are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Common Stock Shares Outstanding i.e., Portage Biotech's Common Stock Shares Outstanding and Non Current Assets Total go up and down completely randomly.
Correlation Coefficient | 0.31 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Most indicators from Portage Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Portage Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.At this time, Portage Biotech's Issuance Of Capital Stock is most likely to increase significantly in the upcoming years. The Portage Biotech's current Enterprise Value is estimated to increase to about 365.1 M, while Selling General Administrative is projected to decrease to roughly 3.6 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Other Operating Expenses | 15.6M | 16.6M | 18.3M | 19.2M | Depreciation And Amortization | 15.6M | 1K | 54K | 51.3K |
Portage Biotech fundamental ratios Correlations
Click cells to compare fundamentals
Portage Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Portage Biotech fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 173.2M | 174.9M | 194.7M | 99.1M | 7.8M | 7.4M | |
| Other Current Liab | 1.9M | 2.9M | 595K | 1.6M | 2.4M | 2.5M | |
| Total Current Liabilities | 2.6M | 3.2M | 783K | 1.9M | 2.9M | 3.0M | |
| Total Stockholder Equity | 96.5M | 101.4M | 121.2M | 76.0M | 4.0M | 3.8M | |
| Net Debt | 509K | (2.6M) | (23.4M) | (10.5M) | (5.0M) | (4.7M) | |
| Retained Earnings | (22.3M) | (38.1M) | (55.0M) | (159.6M) | (239.3M) | (227.4M) | |
| Cash | 3.2M | 2.8M | 23.4M | 10.5M | 5.0M | 3.2M | |
| Non Current Assets Total | 169.4M | 169.9M | 169.8M | 85.5M | 84K | 79.8K | |
| Cash And Short Term Investments | 3.2M | 2.8M | 23.4M | 10.5M | 5.0M | 6.1M | |
| Common Stock Shares Outstanding | 11.0M | 11.7M | 13.1M | 16.1M | 20.3M | 21.4M | |
| Liabilities And Stockholders Equity | 173.2M | 174.9M | 194.7M | 99.1M | 7.8M | 7.4M | |
| Other Stockholder Equity | 58K | 8.0M | 16.9M | 21.2M | 24.4M | 13.3M | |
| Total Liab | 27.5M | 27.3M | 29.2M | 23.7M | 4.5M | 6.1M | |
| Total Current Assets | 3.8M | 4.9M | 24.8M | 13.7M | 7.7M | 7.1M | |
| Common Stock | 117.8M | 130.6M | 158.3M | 218.8M | 219.5M | 230.5M | |
| Short Long Term Debt Total | 3.7M | 3.7M | 150K | 47K | 54.1K | 51.3K | |
| Non Currrent Assets Other | 34K | 58K | 36K | 877K | 49K | 46.6K | |
| Other Assets | 117.4M | 117.4M | 117.4M | 1.0 | 1.15 | 1.09 | |
| Non Current Liabilities Total | 25.0M | 24.1M | 28.4M | 21.9M | 1.6M | 1.5M | |
| Other Current Assets | 14K | 1.5M | 1.3M | 2.4M | 2.6M | 2.8M | |
| Accounts Payable | 343K | 113K | 188K | 274K | 482K | 304.4K | |
| Net Receivables | 60K | 2.2M | 209K | 682K | 39K | 37.1K | |
| Accumulated Other Comprehensive Income | 32K | 82K | 958K | (4.3M) | 23.8M | 25.0M | |
| Net Tangible Assets | 56.4M | 53.2M | 58.1M | 77.9M | 89.6M | 57.7M | |
| Long Term Investments | 6.4M | 8.6M | 9.1M | 9.1M | 2.9M | 0.0 | |
| Net Invested Capital | 100.2M | 101.6M | 121.2M | 76.0M | 4.0M | 3.8M | |
| Net Working Capital | 1.2M | 1.7M | 24.0M | 11.8M | 4.8M | 8.8M | |
| Capital Stock | 117.8M | 130.6M | 158.3M | 218.8M | 219.5M | 176.2M |
Currently Active Assets on Macroaxis
When determining whether Portage Biotech is a strong investment it is important to analyze Portage Biotech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Portage Biotech's future performance. For an informed investment choice regarding Portage Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (68.17) | Return On Assets (0.19) | Return On Equity (1.91) |
The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.